KIT and melanoma: As melanoma is characterized by activation of MAPK signaling due to mutations in BRAF, NRAS, NF1 and KIT genes, this suggests that further hyperactivation of MAPK signaling through loss of inhibitors of this signaling pathway may be deleterious to melanoma cells.